- 专利标题： MUTATED INTERLEUKIN-34 (IL-34) POLYPEPTIDES AND USES THEREOF IN THERAPY
-
申请号： US17422556申请日： 2020-01-15
-
公开(公告)号： US20220098264A1公开(公告)日： 2022-03-31
- 发明人: Carole GUILLONNEAU , Ignacio ANEGON , Erwan MORTIER , Agnès QUEMENER
- 申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES
- 申请人地址： FR Paris; FR Nantes
- 专利权人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ DE NANTES
- 当前专利权人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ DE NANTES
- 当前专利权人地址： FR Paris; FR Nantes
- 优先权： EP19305046.5 20190115
- 国际申请： PCT/EP2020/050920 WO 20200115
- 主分类号： C07K14/54
- IPC分类号： C07K14/54 ; C12N5/0786
摘要：
Interleukin-34 is a cytokine that is involved in the differentiation and survival of macrophages, monocytes, and dendritic cells in response to inflammation. The involvement of IL-34 has been shown in areas as diverse as neuronal protection, autoimmune diseases, infection, cancer, and transplantation. Recent work has also demonstrated a new and possible therapeutic role for IL-34 as a Foxp3+ Treg-secreted cytokine mediator of transplant tolerance. New mutated IL-34 polypeptides have been generated, which can be used as agonists or antagonists.
信息查询
